[1]Demedts IK, Brusselle GG, Bracke KR, et al.Matrix metalloproteinases in asthma and COPD[J]. Curr Opin Pharmacol, 2005,5(6):257-263.
[2]中华医学会呼吸病学分会哮喘学组.支气管哮喘防治指南(支气管哮喘的定义、诊断、治疗及教育和管理方案)[J].中华结核和呼吸杂志,2003,26(2):132-138.
[3]Han Z, Jun X, Zhong N. Expression of matrix metalloproteinases MMP-9 within the airways in asthma[J]. Respir Med, 2003,97(9):563-567.
[4]王秀丽,李淑兰. 诱导痰与呼吸系统疾病[J]. 临床内科杂志,2008,25(8):574-576.
[5]Matsmoto H,Niimi A,Takemura M,et al. Relationship of airway wall thickening to an imbalance between matrix metalloproteinase-9 and its inhibitor in asthma[J]. Thorax,2005,60(12):277-281.
[6]Lee KS, Jin SM, Lee H, et al. Imbalance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in toluene diisocyanate-induced asthma[J]. Clin Exp Allergy, 2004,34(5):276-284.
[7]Bosse M, Chakir J, Rouabhia M, et al. Serum matrix metalloproteinase-9:tissue inhibitor of metalloproteinase-1 ratio correlates with steroid responsiveness in moderate to severe asthma[J]. Am J Respir Crit Care Med,1999,159(6):596-602.
[8]Bergeron C, Page N, Barbeau B, et al. Interleukin-4 promotes airway remodeling in asthma: regulation of procollagen I (alpha1) gene by interleukin-4[J]. Chest, 2003,123(3 Suppl):424S.